Introduction {#Sec1}
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Keratoacanthoma (KA) is a pruritic and rapidly growing cutaneous neoplasm that appears most frequently in sun-exposed regions and intertriginous areas of elderly people \[[@CR1]\]. It bears a close histopathological similarity to squamous cell carcinoma (SCC) and is essentially classified as a low-risk SCC originating from the hair follicle \[[@CR1]\]. The predilection for sun-exposed sites supports a pathogenetic role for ultraviolet radiation in KA. The National Comprehensive Cancer Network guideline recommends wide surgical excision or Mohs micrographic surgery for the treatment of local, low-risk SCC \[[@CR1]\]. Alternative treatments for patients refusing surgery or for neoplasms arising in areas where surgery is difficult to perform may be required; these include cryosurgery, intralesional application of 5-fluorouracil, methotrexate, or interferon α-2a, radiation therapy, and systemic oral retinoids \[[@CR2], [@CR3]\].

Electrochemotherapy (ECT) is a loco-regional therapy characterized by the application of permeabilizing electric pulses on tumors after the systemic or intralesional administration of a chemotherapy drug \[[@CR4]\]. ECT is presently used as first-line therapy in an adjuvant fashion in veterinary oncology, since it has been proved to improve the efficacy of chemotherapeutic agents and their uptake by the neoplastic cells, especially the anti-cancer chemotherapy drug bleomycin, resulting in enhanced local control of the neoplasia \[[@CR5], [@CR6]\]. In humans, the use of ECT was initially limited to the palliation of cutaneous metastases of melanoma \[[@CR7]\], and several phase II trials are ongoing for different tumor types with promising results \[[@CR8]\]. In particular, ECT is emerging as a valid therapeutic and palliative treatment for cutaneous and subcutaneous malignancies, including SCC. In comparison to other standard treatments, such as surgery or radiotherapy, ECT has the additional advantage of rapid action on multiple lesions and with repeated sessions in the absence of significant side effects and with no functional impairment \[[@CR7]\]. Recently, our research group has proposed a novel protocol for ECT involving the adoption of bursts of rectangular and biphasic pulses with a selectable period of repetition \[[@CR9]\]. This protocol has been shown to decrease the morbidity of the treated animals and to improve the clinical outcome. It has been already successfully used in humans for the treatment of large viral warts \[[@CR10]\].

Case Report {#Sec2}
===========

We report the case of a 86-year-old man with an eruptive, pruriginous KA for 3 months on the shoulder. The lesion size was 11.20 × 12.20 mm (Fig. [1](#Fig1){ref-type="fig"}a, c). Clinical and dermoscopic images of the lesions were taken using a Canon EOS Rebel T6i Twin-Flash RL camera (Canfield Scientific Inc., Parsippany, NJ, USA) followed by punch biopsy to confirm histologically the diagnosis of KA (Fig. [1](#Fig1){ref-type="fig"}a′). The patient refused surgical treatment; therefore, an alternative approach involving ECT was proposed. The patient was thoroughly informed about the procedure and signed a consent form. The tumor area was anesthetized with a subcutaneous injection (1 cc) of mepivacaine 2%. The patient was then treated with trains of eight biphasic pulses at a voltage of 700 V/cm and pulse repetition frequency of 1 Hz, which lasted 50 + 50 µs with a 300-µs interpulse (total treatment time per train 3.2 ms), generated by an electroporator (Onkodisruptor®; Biopulse S.r.l., Naples, Italy). The pulses were delivered using caliper electrodes. Immediately after the pulses, bleomycin at a concentration of 1 mg/cm^3^ was injected into the tumor at a depth of about 1.5 mm to a final volume of 1 cc. The treatment was well tolerated, and the patient did not report any discomfort after the intervention. Local response was assessed after 10 weeks from the procedure, and an objective response was observed. The patient reported only scar tissue within the total resolution of the pre-existing KA (Fig. [1](#Fig1){ref-type="fig"}b, d).Fig. 1**a** Keratoacanthoma at presentation. Inset (**a′**) shows the histological appearance of the tumor (hematoxylin/eosin, ×10). **b** Dermoscopy: crateriform central hyperkeratosis. **c** Appearance at 71-day follow-up dermoscopy. **d** Appearance at 71-day follow-up dermoscopy: residual erythema and crusts

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (ethical code of the Università degli Studi della Campania "L. Vanvitelli", approved with D.R. 992/2012) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from the patient for being included in the study.

Discussion {#Sec3}
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Surgical excision is the treatment of choice for the majority of cases of KA. However, surgical treatment can result in functional and aesthetic defects, especially when the lesion is large or located in cutaneous areas that are difficult to treat with surgery. In these latter cases, an effective nonsurgical treatment would be more appropriate. We report here an alternative therapeutic approach for KA, namely, the use of ECT combined with intralesional bleomycin injection. The indications for ECT are primitive or relapsing tumors of the skin or subcutaneous tissue of many different histological types \[[@CR11]\]. Tumor size strongly influences the response. Lesions whose largest diameter does not exceed 3 cm show a higher complete response rate than neoplasms, as previously described \[[@CR7]\]. ECT has been shown in clinical trials to have a high response rate in the treatment of patients with primary or metastatic skin cancers \[[@CR8]\]. Interestingly, ECT has been already successfully used to treat eruptive KAs \[[@CR12]\]. In the case presented here, the patient showed an excellent response to the ECT treatment and at the moment of writing this report is well. This good result is in accordance with our previous work on ECT treatment of cutaneous pathologies which showed that the majority of patients had no or mild pain after ECT \[[@CR10]\]. This study, together with the work of Ribero et al. \[[@CR12]\], suggests that ECT can be considered as an excellent alternative to current therapies in the treatment of KA. Nevertheless, it must be considered that KA can spontaneously regress; therefore, more cases are necessary to exactly define the impact of ECT on the clinical history of KA.

Conclusions {#Sec4}
===========

Electrochemotherapy has several advantages over radiotherapy for the treatment of such conditions as radio-dermatitis, lymphedema, and secondary cancers, including its simplicity and lack of complications \[[@CR7]\]. We suggest that it could be an effective alternative treatment for KA, especially for patients who refuse surgery or whose conditions are not suitable for a surgical procedure. Larger, controlled clinical studies are required to confirm its safety and efficacy for the treatment of KA as well as for other skin malignancies.
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